Cabezón, M., Arenillas Rocha, L., Zamora, L., & Group, C. (2021). Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Chicago Style CitationCabezón, Marta, Leonor Arenillas Rocha, Lurdes Zamora, and CETLAM Group. Different Methylation Signatures At Diagnosis in Patients With High-risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Predict Azacitidine Response and Longer Survival. 2021.
MLA CitationCabezón, Marta, Leonor Arenillas Rocha, Lurdes Zamora, and CETLAM Group. Different Methylation Signatures At Diagnosis in Patients With High-risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Predict Azacitidine Response and Longer Survival. 2021.